The Parkinson's disease therapy developer completed a series A round co-led by AbbVie Ventures, which will also take a board seat at the company.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Grand Pharmaceutical invested $5.6m in Cloudbreak through a licensing agreement, as part of a $25.4m round for the ocular disorder therapy developer.

Cash Capital provided up to $42.4m for the iris recognition technology developer, following a Gree Electric investment in September.

Osaka-founded Kringle has increased its round to $15.5m thanks to investors including OUVC in order to fund development of its rare disease treatments.

MicroPort Scientific's cardiovascular technology spinoff secured $130m at a $1.1bn valuation, with the cash to fund R&D, manufacturing and market growth.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Novo has backed automated molecule and material discovery business Kebotix, co-founded by former Harvard University professor Alán Aspuru-Guzik.

The E-Town Biomedical Park-backed biopharmaceutical company, which has some 15 assets in clinical trials, has completed a two-tranche series C round.